FINNENCE ▪ THE WIRE FILE
THE WIRE · № 77847
News■ Unclear/unknown
EU approves Kimberly-Clark's acquisition of Kenvue, subject to conditions
KINDNews
DIRECTION■ Unclear/unknown
SOURCES2
ENTITIES2
STORY SIZE2 RECORDS
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
EU conditional approval of Kimberly-Clark's Kenvue acquisition advances a large consumer-health deal, relevant to both names.
Mega consumer-health deal advances
CATALYST TO WATCH
Remaining regulatory approvals
MAIN RISK
Conditions or further hurdles delay close
02 THE STORY SO FAR
THE RECORD, IN ORDER.
UPDATED 2 TIMES · FIRST · LAST2026-10-13 14:16 UTCNewsEU approves Kimberly-Clark's acquisition of Kenvue, subject to conditionsCURRENT RECORD
2026-10-13 15:29 UTCNewsEU approves Kimberly-Clark's $40 billion Kenvue acquisition
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDConsumer
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Consumer
Thousands of homeowners face adjustable-rate mortgage resets — and much higher payments2026-10-13 13:35 UTC
Thousands of homeowners face adjustable-rate mortgage resets — and much higher payments2026-10-13 13:35 UTC
→CORRELATIONshares Consumer
Can CAKE's Strong Traffic Offset Persistent Restaurant Cost Inflation?2026-10-13 13:35 UTC
Can CAKE's Strong Traffic Offset Persistent Restaurant Cost Inflation?2026-10-13 13:35 UTC
→CORRELATIONshares Consumer
Gigasun AB (publ) (GIGA) Converts SEK 21.1M Bonds to Equity, Debt Down to SEK 49.2M2026-10-13 14:15 UTC
Gigasun AB (publ) (GIGA) Converts SEK 21.1M Bonds to Equity, Debt Down to SEK 49.2M2026-10-13 14:15 UTC
→CORRELATIONshares Consumer
Albertsons demands over $9bn from Kroger following merger collapse2026-10-13 14:43 UTC
Albertsons demands over $9bn from Kroger following merger collapse2026-10-13 14:43 UTC
→CORRELATIONshares Healthcare
‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks2026-10-13 15:17 UTC
‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks2026-10-13 15:17 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.